HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Karen Chak Selected Research

OGT 719

1/2004A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Karen Chak Research Topics

Disease

2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2007 - 01/2005
1Disease Progression
09/2007
1Neutropenia
09/2007
1Hepatocellular Carcinoma (Hepatoma)
01/2004
1Liver Neoplasms (Liver Cancer)
01/2004
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2002

Drug/Important Bio-Agent (IBA)

2Cisplatin (Platino)FDA LinkGeneric
09/2007 - 01/2005
2Etoposide (VP 16)FDA LinkGeneric
01/2005 - 10/2002
1Irinotecan (Camptosar)FDA LinkGeneric
09/2007
1Docetaxel (Taxotere)FDA Link
09/2007
1GemcitabineFDA Link
01/2005
1PlatinumIBA
01/2005
1OGT 719IBA
01/2004
1Asialoglycoprotein ReceptorIBA
01/2004
1Topoisomerase I InhibitorsIBA
10/2002
1Topotecan (Hycamtin)FDA LinkGeneric
10/2002

Therapy/Procedure

1Drug Therapy (Chemotherapy)
09/2007